Hind.Organ.Chem.

Which are the latest news on Hind.Organ.Chem.?

Why is Hindustan Organic Chemicals Ltd falling/rising?

As of 10-Jun, Hindustan Organic Chemicals Ltd's stock price is at 38.31, down 0.93% after five consecutive days of decline totaling 9.69%. Despite this short-term drop, the stock has risen 11.17% over the past month and 19.94% year-to-date, with increasing investor interest indicated by a significant rise in delivery volume.

As of 10-Jun, Hindustan Organic Chemicals Ltd's stock price is currently at 38.31, reflecting a decrease of 0.36, or 0.93%. The stock has been on a downward trend, having fallen for the last five consecutive days, resulting in a total decline of 9.69% over the past week. This performance is notably worse than the benchmark Sensex, which has only decreased by 0.49% during the same period.<BR><BR>Despite this recent decline, the stock has shown positive performance over longer time frames, with an increase of 11.17% over the past month and a year-to-date rise of 19.94%. Additionally, the stock has outperformed the sector today by 0.65%. <BR><BR>Investor participation appears to be increasing, as evidenced by a delivery volume of 1.31 lacs on June 9, which is up by 52.34% compared to the five-day average. This suggests that while the stock is currently experiencing a decline, there is a growing interest among investors. The stock's liquidity remains adequate for trading, as it is based on 2% of the five-day average traded value.<BR><BR>In summary, the current fall in Hindustan Organic Chemicals Ltd's stock price can be attributed to its recent consecutive losses, despite its strong performance over longer periods and increasing investor participation.

What does Hind.Organ.Chem. do?

Hindustan Organic Chemicals Ltd is a micro-cap company that produces bulk industrial chemicals and intermediates, established in 1960 to promote self-reliance in organic chemicals. As of March 2026, it reported net sales of 136 Cr and a net profit of 16 Cr.

Overview: <BR>Hindustan Organic Chemicals Ltd is engaged in the business of bulk industrial chemicals and chemical intermediates within the commodity chemicals industry, categorized as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1960 by the Government of India, Hindustan Organic Chemicals Ltd was established to achieve self-reliance in basic organic chemicals needs. Initially starting as a small chemical unit, it has grown into a multi-unit company with two fast-growing units and one subsidiary. The latest reported quarterly results show net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 136 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 16 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 256 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.03 <BR>Return on Equity: -1.92% <BR>Price to Book: 0.25 <BR><BR>Contact Details: <BR>Address: 401 402 403 4th Flr V Times Sq, Plot No 3 Sec-15 CBD Belapur Navi Mumbai Maharashtra : 400614 <BR>Tel: 91-22-27575268/69 <BR>Email: rasayani.cs@hocl.gov.in <BR>Website: http://www.hocl.gov.in

Should I buy, sell or hold Hindustan Organic Chemicals Ltd?

Are Hindustan Organic Chemicals Ltd latest results good or bad?

Hindustan Organic Chemicals Ltd's latest results show a significant quarterly profit increase of 500.51% to ₹15.70 crore, but a 7.39% decline in net sales and ongoing operational challenges indicate mixed performance. While the profit improvement is positive, concerns about revenue volatility and fundamental weaknesses remain.

Hindustan Organic Chemicals Ltd's latest results present a mixed picture. On one hand, the company reported a significant increase in net profit for Q4 FY26, achieving ₹15.70 crore, which is a remarkable 500.51% improvement quarter-on-quarter. This turnaround in profitability is primarily attributed to a reduction in interest expenses and better operating performance.<BR><BR>However, when looking at net sales, the company experienced a decline of 7.39% compared to the previous quarter, totaling ₹136.36 crore. This decline continues a trend of revenue volatility, as sales were nearly flat year-on-year as well. Furthermore, the full-year performance reveals persistent operational challenges, with an operating loss of ₹86 crore for FY25, indicating that the company has struggled significantly over the longer term.<BR><BR>While the operating margin improved to 12.21% from a negative margin in the previous quarter, the overall financial health of the company raises concerns. The negative return on equity and return on capital employed further highlight the fundamental weaknesses in its business model.<BR><BR>In summary, while the quarterly profit improvement is a positive sign, it is overshadowed by ongoing operational struggles and revenue declines. Therefore, the latest results can be seen as a cautious positive, but the broader context suggests significant challenges remain.

How has been the historical performance of Hind.Organ.Chem.?

Hind.Organ.Chem. experienced significant fluctuations in financial performance, with net sales declining from INR 703.89 crore in March 2024 to INR 535.87 crore in March 2025, while profitability improved markedly, resulting in a profit after tax of INR 391.54 crore in March 2025 compared to a loss the previous year. Despite challenges, the company showed resilience with a positive cash flow turnaround.

Answer:<BR>The historical performance of Hind.Organ.Chem. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Hind.Organ.Chem. experienced a decline in net sales from INR 703.89 crore in March 2024 to INR 535.87 crore in March 2025, following a peak of INR 631.44 crore in March 2023. The total operating income mirrored this trend, decreasing to INR 535.87 crore in March 2025 from INR 703.89 crore in the previous year. The company faced rising raw material costs, which were INR 426.95 crore in March 2025, up from INR 503.05 crore in March 2024. Operating profit (PBDIT) turned negative, recording -INR 63.38 crore in March 2025, a stark contrast to the positive INR 15.70 crore in March 2024. Profit before tax also improved significantly to INR 394.87 crore in March 2025 from a loss of -INR 55.32 crore in March 2024, leading to a profit after tax of INR 391.54 crore in March 2025, compared to a loss of -INR 55.32 crore the previous year. The company's total assets decreased slightly to INR 1,564.37 crore in March 2025 from INR 1,572.34 crore in March 2024, while total liabilities also saw a reduction to INR 1,564.37 crore from INR 1,572.34 crore. Cash flow from operating activities showed a positive turnaround, reaching INR 631 crore in March 2025, compared to a negative cash flow of -INR 65 crore in March 2024. Overall, the company has shown resilience with a notable recovery in profitability despite challenges in sales and operating margins.

When is the next results date for Hind.Organ.Chem.?

Hind.Organ.Chem. will announce its results on 13 August 2025.

Hind.Organ.Chem. will declare its results on 13 August 2025.

How big is Hind.Organ.Chem.?

As of 24th July, Hindustan Organic Chemicals Ltd has a market capitalization of 247.00 Cr, with recent net sales of 535.86 Cr and a net profit of 391.77 Cr. The latest balance sheet shows shareholder's funds at a loss of 51.43 Cr and total assets valued at 1,572.34 Cr.

As of 24th July, Hindustan Organic Chemicals Ltd has a market capitalization of 247.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 535.86 Cr and a Net Profit of 391.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds at a loss of 51.43 Cr and Total Assets valued at 1,572.34 Cr.

Who are in the management team of Hind.Organ.Chem.?

As of March 2022, the management team of Hind.Organ.Chem. includes Sajeev B (Chairman & Managing Director), Bharat J. Kanabar and Pratyush Mandal (Non Official Independent Directors), Yogendra Prasad Shukla (Director of Finance & CFO), and several government nominees: Satendra Singh, Kanisk Kant Srivastava, and Sanjay Rastogi, along with Subramonian H (Company Secretary & Compliance Officer).

As of March 2022, the management team of Hind.Organ.Chem. includes the following individuals:<BR><BR>1. Sajeev B - Chairman & Managing Director<BR>2. Bharat J. Kanabar - Non Official Independent Director<BR>3. Pratyush Mandal - Non Official Independent Director<BR>4. Subramonian H - Company Secretary & Compliance Officer<BR>5. Yogendra Prasad Shukla - Director (Finance) & CFO<BR>6. Satendra Singh - Nominee (Government)<BR>7. Kanisk Kant Srivastava - Nominee (Government)<BR>8. Sanjay Rastogi - Nominee (Government) <BR><BR>This team is responsible for overseeing the operations and governance of the company.

Is Hind.Organ.Chem. overvalued or undervalued?

Hind.Organ.Chem. is currently assessed as undervalued and risky, with key ratios indicating financial distress, contrasting sharply with competitors like Solar Industries and Godrej Industries, making it a potential buying opportunity for risk-tolerant investors despite a year-to-date stock decline of 15.24%.

As of 1 November 2021, Hind.Organ.Chem. has moved from a valuation grade of very expensive to risky. The company is currently assessed as undervalued. Key ratios include a PE ratio of -2.15, an EV to EBITDA of -2.14, and an EV to Sales of 0.34, which indicate significant financial distress compared to its peers.<BR><BR>In comparison, Solar Industries, rated very expensive, has a PE ratio of 123.77, while Godrej Industries, rated attractive, has a PE ratio of 46.63. These ratios highlight the stark contrast in valuation between Hind.Organ.Chem. and its competitors. Despite recent stock performance showing a decline of 15.24% year-to-date compared to a 5.63% gain in the Sensex, the company's low valuation ratios suggest it may present a buying opportunity for investors willing to take on higher risk.

What is the technical trend for Hind.Organ.Chem.?

As of May 20, 2025, Hind.Organ.Chem. shows a mildly bearish trend, with daily indicators indicating bearish momentum despite some weekly bullish signals.

As of 20 May 2025, the technical trend for Hind.Organ.Chem. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating bearish momentum. The weekly MACD is mildly bullish, but the monthly MACD and Bollinger Bands are both bearish, suggesting weakness in the longer term. The RSI on a monthly basis is also bearish, reinforcing the negative outlook. Overall, while there are some bullish signals on the weekly indicators, the prevailing trend remains bearish, particularly in the daily and monthly assessments.

Who are the top shareholders of the Hind.Organ.Chem.?

The top shareholders of Hind.Organ.Chem. include the President of India with a 58.78% stake, while individual investors hold 34.63%. There are no pledged promoter holdings, mutual funds, or foreign institutional investors involved.

The top shareholders of Hind.Organ.Chem. are primarily the promoters, with the President of India holding the largest stake at 58.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, individual investors hold 34.63% of the shares. There are no significant public shareholders listed.

Has Hind.Organ.Chem. declared dividend?

No Dividend History Available

Who are the peers of the Hind.Organ.Chem.?

Peers of Hind.Organ.Chem. include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, and others. Hind.Organ.Chem. has a 1-year return of -20.65%, with management risk rated as below average.

Peers: The peers of Hind.Organ.Chem. are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, ARCL Organics, Oriental Carbon, Kanchi Karpooram, IVP, and ZRZ Bioenergy.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and ARCL Organics, while Good management risk is found at Chemplast Sanmar and the rest. Average management risk is present at Tata Chemicals, India Glycols, Oriental Carbon, Kanchi Karpooram, and IVP, while Below Average management risk is noted at Fischer Medical, Hind.Organ.Chem., and ZRZ Bioenergy. Growth is rated as Good for IVP, while Below Average growth is seen at Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Oriental Carbon, Kanchi Karpooram, and the rest. Average growth is noted at Fischer Medical and ZRZ Bioenergy. Capital Structure is rated as Excellent for GHCL and Oriental Carbon, Good for Fischer Medical and ARCL Organics, Average for Tata Chemicals, India Glycols, Hind.Organ.Chem., and IVP, and Below Average for Chemplast Sanmar and Kanchi Karpooram.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ARCL Organics at 376.04%, while the lowest is Oriental Carbon at -67.41%. Hind.Organ.Chem. has a 1-year return of -20.65%, which is higher than Oriental Carbon's but lower than ARCL Organics'. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Oriental Carbon, Kanchi Karpooram, and IVP.